Rocatinlimab represents a highly specialized humanized IgG1 monoclonal antibody specifically engineered to target the OX40 receptor (CD134) with exceptional binding affinity. It effectively facilitates the measurable blockade of the OX40-OX40L co-stimulatory axis while simultaneously inducing the targeted depletion of OX40-positive activated T cells through antibody-dependent cellular cytotoxicity (ADCC) across various preclinical experimental models to evaluate the restoration of immune homeostasis during strictly monitored laboratory observation periods.
CAS Number:
[2431972-52-8]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
